Mayo Clinic approves Clinical Study of HeraBEAT
Filed with ASX · · 3 pages · English
HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, is pleased to announce that the Mayo Clinic’s Institutional Review Board (IRB) has approved the launch of a Clinical Study of the HeraBEAT device and the HeraCARE platform to review foetal and matern
Story so far
Earlier from HeraMED
- Partnership to Launch HeraCARE & HeraBEAT with Teleperinatal
- Partnership with eCare21 & functional integration completed
- Clinical & Functional Validation of HeraBEAT Achieved at JHC
- Partnership with Leading Virtual Care Platform eCare21 in US
- Updated Quarterly Activities Report
Later from HeraMED
- Completion of AUD 2.3M Placement
- Israels Largest Healthcare Provider Begins Pilot Study
- HeraCARE commercial agreement with Joondalup Health Campus
- Pilot agreement signed with US leader Obstetrix Medical
- HeraCARE paid pilot commences at Joondalup Health Campus
Follow HeraMED into a list and get an email when it puts out news.
Follow HeraMED